P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Cough is among the most common complaints for which patients worldwide seek medical attention. In a majority of patients with chronic cough (defined as cough of greater than 8 weeks' duration), successful management results from a thorough evaluation and treatment of underlying causes. In a subgroup of patients, however, cough proves refractory to therapeutic trials aimed at known reversible causes of chronic cough. Such patients are appropriately termed as having refractory chronic cough. At present, safe and effective medications are lacking for this challenging patient population. Currently available therapeutic options are usually ineffective or achieve antitussive effect at the expense of intolerable side effects, typically sedation. Fortunately, the past decade has witnessed great progress in elucidating underlying mechanisms of cough. From that knowledge, aided by the development of validated instruments to measure objective and subjective cough-related end points, numerous antitussive drug development programs have emerged. The most active area of inquiry at present involves antagonists of the purinergic P2X receptors. Indeed, four clinical programs (one in Phase 3 and three in Phase 2) are currently underway investigating antagonists of receptors comprised entirely or partially of the P2X3 subunit as potential antitussive medications. Herein we review the foundation on which P2X receptor antagonists were developed as potential antitussive medications and provide an update on current clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Burnstock, G. (1972) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06930-3 · Cited by 1,852
Nomenclature and classification of purinoceptors.
Fredholm, B. B., Abbracchio, M. P., Burnstock, G., Daly, J. W., Harden, T. K., Jacobson, K. A., Leff, P., & Williams, M. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06782-1 · Cited by 1,585
Birring, S. S. (2003) · Thorax · doi:10.1136/thorax.58.4.339 · Cited by 1,062
Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice
Cockayne, D. A., Hamilton, S. G., Zhu, Q.-M., Dunn, P. M., Zhong, Y., Novakovic, S., Malmberg, A. B., Cain, G., Berson, A., Kassotakis, L., et al. (2000) · Nature · doi:10.1038/35039519 · Cited by 1,030
Cellular function and molecular structure of ecto-nucleotidases
Zimmermann, H., Zebisch, M., & Sträter, N. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9309-4 · Cited by 977
New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor
Brake, A. J., Wagenbach, M. J., & Julius, D. (1994) · Nature · doi:10.1038/371519a0 · Cited by 919
ERS guidelines on the diagnosis and treatment of chronic cough in adults and children
Morice, A. H., Millqvist, E., Bieksiene, K., Birring, S. S., Dicpinigaitis, P., Domingo Ribas, C., Hilton Boon, M., Kantar, A., Lai, K., McGarvey, L., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01136-2019 · Cited by 893
Self-citationATP Signaling Is Crucial for Communication from Taste Buds to Gustatory Nerves
Finger, T. E., Danilova, V., Barrows, J., Bartel, D. L., Vigers, A. J., Stone, L., Hellekant, G., & Kinnamon, S. C. (2005) · Science · doi:10.1126/science.1118435 · Cited by 818
Ferguson, D. R., Kennedy, I., & Burton, T. J. (1997) · The Journal of Physiology · doi:10.1111/j.1469-7793.1997.503bb.x · Cited by 653
Signaling at Purinergic P2X Receptors
Surprenant, A., & North, R. A. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100630 · Cited by 547
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
Estornut, C., Milara, J., Bayarri, M. A., Belhadj, N., & Cortijo, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794997 · Cited by 161
Chronic cough: new insights and future prospects
Morice, A. H., Dicpinigaitis, P. V., McGarvey, L. P., & Birring, S. S. (2021) · European Respiratory Review · doi:10.1183/16000617.0127-2021 · Cited by 151
Self-citationDavenport, A. J., Berindan‐Neagoe, I., Bräuer, N., Koch, M., Rotgeri, A., Nagel, J., Laux‐Biehlmann, A., Machet, F., Coelho, A.-M., Boyce, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99177-0 · Cited by 73
Sapio, M. R., Vazquez, F. A., Loydpierson, A. J., Maric, D., Kim, J., LaPaglia, D. M., Puhl, H. L., Lu, V. B., Ikeda, S. R., Mannes, A. J., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.615362 · Cited by 49
Metadata
- Authors
- Dicpinigaitis, P. V., McGarvey, L. P., & Canning, B. J.
- Affiliations
- Albert Einstein College of Medicine (US)
- Queen's University Belfast (GB)
- Johns Hopkins University (US)
- Corresponding author
- Dicpinigaitis, Peter V.
- Venue
- Lung
- Published
- 2020-07-13
- Volume
- 198
- Issue
- 4
- Pages
- 609-616
- ISSN
- 0341-2040 (ISSN-L)
- 1432-1750
- OpenAlex
- W3043367146
- Cited by
- 57
- References
- 67
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 7 · 2021: 14 · 2020: 6
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- green
- pure.qub.ac.uk
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Lung (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, other-oa)
- Funders
- National Heart, Lung, and Blood Institute (R01HL141251)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory and Cough-Related Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- P2X3 receptor antagonist, antitussive agents, chronic cough, refractory chronic cough, purinergic receptors, cough mechanism, clinical trials, drug development
- MeSH terms
- Benzenesulfonamides, Ageusia, Antitussive Agents, Chronic Disease, Clinical Trials as Topic, Cough, Humans, Imidazoles, Piperidines, Pyridines, Pyrimidines, Sulfonamides, Receptors, Purinergic P2X3, Purinergic P2X Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough. https://app.cochat.ai/papers/10.1007/s00408-020-00377-8
- The paper
- Dicpinigaitis, P. V., McGarvey, L. P., & Canning, B. J. (2020). P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough. Lung. https://doi.org/10.1007/s00408-020-00377-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.